JP2943247B2 - Hypnosis / Sedative - Google Patents
Hypnosis / SedativeInfo
- Publication number
- JP2943247B2 JP2943247B2 JP2143774A JP14377490A JP2943247B2 JP 2943247 B2 JP2943247 B2 JP 2943247B2 JP 2143774 A JP2143774 A JP 2143774A JP 14377490 A JP14377490 A JP 14377490A JP 2943247 B2 JP2943247 B2 JP 2943247B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- sedative
- hypnotic
- western
- chabo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000147 hypnotic effect Effects 0.000 title claims description 17
- 230000001624 sedative effect Effects 0.000 title claims description 15
- 239000000932 sedative agent Substances 0.000 title claims description 13
- 239000000739 antihistaminic agent Substances 0.000 claims description 10
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical group CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 8
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical group OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000001387 anti-histamine Effects 0.000 claims description 8
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 8
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 240000008440 Passiflora incarnata Species 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960004646 diphenhydramine tannate Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ この発明は西洋チャボ時計草抽出エキスと抗ヒスタミ
ン性物質とを有効成分として含有する新規な催眠・鎮静
剤に関するものであり、医療の分野で利用される。Description: TECHNICAL FIELD The present invention relates to a novel hypnotic / sedative agent containing an extract of western chabo watchgrass extract and an antihistamine substance as active ingredients. Used.
［従来技術］ 西洋チャボ時計草（学名;Passiflora incarnata L,パ
ッシフローラ インカルナタ エル）は中南米原産の一
年草であり、鎮静・催眠作用を生じさせる成分としてHa
rman Alkaroides（ハーマン アルカロイズ）を含有し
ており、ヨーロッパでは17世紀頃から鎮静・催眠作用を
有する民間薬として用いられており、今なら繁用されて
いる。[Prior Art] The western bamboo watch grass (scientific name: Passiflora incarnata L) is an annual plant native to Latin America, and is an ingredient that causes sedation and hypnosis.
It contains rman Alkaroides and has been used as a folk medicine with sedative and hypnotic effects since the 17th century in Europe, and is now widely used.
国内では西洋チャボ時計草抽出エキスは、錠剤の形状
で主に鎮静剤として販売されている。In Japan, the extract of western chabo watch grass is mainly sold as a sedative in the form of tablets.
一方、種々の抗ヒスタミン性物質は風邪薬や他の多く
の治療薬に有効成分として配合されており、その作用の
一つとして催眠・鎮静作用を有していることが知られて
いる。On the other hand, various antihistamines have been formulated as active ingredients in cold medicines and many other therapeutic agents, and are known to have a hypnotic / sedative effect as one of the effects.
抗ヒスタミン性物質の中で、塩酸ジヒェンヒドラミン
は米国で催眠剤として用いられている。Among the antihistamines, dichenhydramine hydrochloride is used as a hypnotic in the United States.
［発明が解決しようとする課題］ この発明は、西洋チャボ時計草抽出エキスと抗ヒスタ
ミン性物質とを併用することにより、これらをそれぞれ
単独で使用した場合に比べて、著しく催眠・鎮静作用が
増強された薬剤を得ることを目的としてなされたもので
ある。[Problems to be Solved by the Invention] The present invention significantly enhances the hypnotic and sedative effects by using a combination of the extract of western chabo clockgrass and an antihistamine substance as compared with the case where these are used alone. The purpose is to obtain a given drug.
［課題を解決するための手段］ この発明における西洋チャボ時計草抽出エキスは、西
洋チャボ時計草の浸出液を濃縮して得られるものであ
る。[Means for Solving the Problems] The extract of western chabo watchgrass according to the present invention is obtained by concentrating the exudate of western chabo watchgrass.
またこの発明における抗ヒスタミン性物質としては、
例えば塩酸ジフェンヒドラミン、サリチル酸ジフェンヒ
ドラミン、タンニン酸ジフェンヒドラミン、ラウリル硫
酸ジフェンヒドラミン、マレイン酸クロルフェニラミ
ン、マレンイン酸カービノキサミンなどが挙げられる。Further, as the antihistamine substance in the present invention,
For example, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tannate, diphenhydramine lauryl sulfate, chlorpheniramine maleate, carbinoxamine maleate and the like can be mentioned.
この発明の催眠・鎮静剤は、西洋チャボ時計草抽出エ
キスと上記のような抗ヒスタミン性物質とを有効成分と
して含有してなり、両者の含有割合は特に限定されない
が、好ましくは重量比で抗ヒスタミン性物質１に対して
西洋チャボ時計草抽出エキスは２ないし10000程度であ
る。The hypnotic / sedative according to the present invention contains the extract of the extract of Chinese chamomile clock herb and the above-mentioned antihistamine substance as active ingredients, and the content ratio of both is not particularly limited. The amount of the extract of western chabo clock grass against histamine substance 1 is about 20,000 to 10,000.
この発明の催眠・鎮静剤は、経口投与剤好ましくは固
体状の経口投与剤、例えば錠剤、カプセル剤、細粒剤、
顆粒剤などとして用いられる。The hypnotic / sedative of the present invention is preferably an orally administered drug, preferably a solid orally administered drug such as tablets, capsules, fine granules,
Used as granules and the like.
これらの製剤中に占める有効成分、すなわち西洋チャ
ボ時計草抽出エキスと抗ヒスタミン剤とからなる混合物
の含有割合は10〜30重量％程度である。The content of the active ingredient in these preparations, that is, the content of the mixture consisting of the extract of the extract of western seaweed and the antihistamine is about 10 to 30% by weight.
また、この発明の催眠・鎮静剤における有効成分の投
与量は、剤型、両者有効成分の含有割合、患者の症状等
に応じて適宜選択されるが、一般的には、50〜300mg/
日、好ましくは75〜150mg/日の範囲で投与される。The dose of the active ingredient in the hypnotic / sedative of the present invention is appropriately selected depending on the dosage form, the content ratio of both active ingredients, the symptoms of the patient, and the like.
Daily, preferably in the range of 75-150 mg / day.
この発明の催眠・鎮静剤は、主薬である西洋チャボ時
計草抽出エキスおよび抗ヒスタミン性物質に、例えば乳
糖、デンプン、低置換度ヒドロキシプロピルセルロー
ス、ヒドロキシプロピルメチルセルロース、ステアリン
酸マグネシウム、タルク等の不活性な賦形剤、崩壊剤、
結合剤、滑沢剤等の慣用の添加剤を配合して、慣用の方
法例えば第十一改正日本薬局方に記載の方法と同様にし
て、前記のような剤型に製剤化することができる。また
製剤化の際に必要に応じて、着色剤、矯味剤、矯臭剤等
をさらに配合してもよい。The hypnotic / sedative of the present invention can be used as an active ingredient in inactive substances such as lactose, starch, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, magnesium stearate, talc, etc. Excipients, disintegrants,
Binders, lubricants and other conventional additives are blended, and can be formulated into the above-mentioned dosage form in the same manner as in a conventional method, for example, the method described in the Japanese Pharmacopoeia 11th Edition. . In addition, a coloring agent, a flavoring agent, a flavoring agent, and the like may be further added as needed at the time of formulation.
この発明の催眠・鎮静剤は、不眠症や、緊張感、興奮
感、いらいら感などの鎮静、上記症状に伴う頭重、疲労
倦怠感の緩和、不安感の解消などに用いることができ
る。The hypnotic / sedative of the present invention can be used for sedation of insomnia, nervousness, excitement, irritability, etc., reduction of head weight, fatigue and malaise associated with the above symptoms, and elimination of anxiety.
［効果］ 次にこの発明の催眠・鎮静剤の効果を試験例により説
明する。[Effect] Next, the effect of the hypnotic / sedative of the present invention will be described with reference to test examples.
試験例 体重20〜30gのddy系雌性マウスを１群５匹として用い
た。各マウスに上記薬剤を、それぞれマウス体重当り0.
1ml/10gとなるように１％メチルセルロース溶液に懸濁
して経口投与した。薬剤を含まない１％メチルセルロー
ス溶液を経口投与したものをコントロールとした。Test example Ddy female mice weighing 20 to 30 g were used as 5 mice per group. The above drug was added to each mouse at a rate of 0.
The suspension was orally administered to a 1% methylcellulose solution so as to be 1 ml / 10 g. A control that was orally administered with a 1% methylcellulose solution containing no drug was used as a control.
各薬剤投与40分後に、ヘキソバルビタール注射液（8
2.5mg/kg）を腹腔内投与し、２〜３分後に正向反射の消
失を確認した時点から、再び正向反射が表われるまでの
時間を測定した。40 minutes after each drug administration, hexobarbital injection (8
2.5 mg / kg) was intraperitoneally administered and the time from when the disappearance of the righting reflex was confirmed two to three minutes later until the righting reflex appeared again was measured.
この試験結果から明らかなように、（４）の西洋チャ
ボ時計草抽出エキスとマレイン酸クロルフェニラミンの
併用投与、および（５）の西洋チャボ時計草抽出エキス
��塩酸ジフェンヒドラミンの併用投与では、それぞれの
単独投与すなわち（１）の西洋チャボ時計草抽出エキス
単独投与、（２）のマレイン酸クロルフェニラミン単独
投与、および（３）の塩酸ジフェンヒドラミン単独投与
の場合に比べて、有意に正向反射消失持続時間の延長が
認められ、催眠・鎮静効果が増強されていることがわか
る。 As is evident from the test results, in the combined administration of the extract of western chabo watchgrass and chlorpheniramine maleate in (4) and the combined administration of extract of western chabo watchgrass and diphenhydramine hydrochloride in (5), respectively. Compared with the case of single administration, ie, the administration of (1) the extract of western chabo wilt extract alone, the administration of (2) chlorpheniramine maleate alone, and the administration of (3) diphenhydramine hydrochloride alone, the persistence of righting reflex was significantly longer. Prolonged time was observed, indicating that the hypnotic and sedative effects were enhanced.
［実施例］ 以下に、この発明を実施例により説明する。[Example] Hereinafter, the present invention will be described with reference to examples.
実施例１ 西洋チャボ時計草抽出エ���ス（90g）、塩酸ジフェン
ヒドラミン（25g）、低置換度ヒドロキシプロピルセル
ロース（商品名:L−HPC、信越化学社製）（54g）および
乳糖（344g）の混合物を、ヒドロキシプロピルメチルセ
ルロース（27g）の99％エタノール溶液（54ml）で練合
した後、真空乾燥して乾燥物を得る。Example 1 A mixture of Western charcoal clock grass extract (90 g), diphenhydramine hydrochloride (25 g), low-substituted hydroxypropylcellulose (trade name: L-HPC, manufactured by Shin-Etsu Chemical Co., Ltd.) (54 g) and lactose (344 g) After kneading with a 99% ethanol solution (54 ml) of hydroxypropylmethylcellulose (27 g), the mixture is dried under vacuum to obtain a dried product.
次いでこの乾燥物を20メッシュで整粒して、硬カプセ
ルに充填し硬カプセル剤（3,000カプセル）を得る。Next, the dried product is sized with a 20 mesh and filled into hard capsules to obtain hard capsules (3,000 capsules).
実施例２ 実施例１の塩酸ジフェンヒドラミン（25g）のかわり
に、マレイン酸クロルフェニラミン（7.5g）を用いて、
実施例１と同様にして西洋チャボ時計草抽出エキスとマ
レイン酸クロルフェニラミンを主薬として含有する硬カ
プセル剤（3000カプセル）を得る。Example 2 Instead of diphenhydramine hydrochloride (25 g) of Example 1, chlorpheniramine maleate (7.5 g) was used.
In the same manner as in Example 1, a hard capsule (3000 capsules) containing the extract of the extract of western seaweed watchgrass and chlorpheniramine maleate as main ingredients is obtained.
実施例３ 西洋チャボ時計草抽出エキス 90 ｇ 塩酸ジフェンヒドラミン 25 ｇ ヒドロキシプロピルメチルセルロース 27 ｇ 低置換度ヒドロキシプロピルセルロース 54 ｇ （商品名:L−HPC、信越化学社製）乳糖 341.3g 以上の成分を実施例１と同様に処理して乾燥物を得た
後、これを粉砕し、ステアリン酸マグネシウム（2.7g）
を加え、常法に従って打錠し錠剤（3,000錠）を得る。Example 3 Western charcoal watchgrass extract 90 g Diphenhydramine hydrochloride 25 g Hydroxypropyl methylcellulose 27 g Low-substituted hydroxypropylcellulose 54 g (L-HPC, manufactured by Shin-Etsu Chemical Co., Ltd.) Lactose More than 341.3 g After a dried product was obtained by treating in the same manner as in Example 1, this was pulverized, and magnesium stearate (2.7 g) was obtained.
And tableting is performed according to a conventional method to obtain tablets (3,000 tablets).
実施例４ 実施例３の塩酸ジフェンヒドラミン（25g）のかわり
に、マレイン酸クロルフェニラミン（7.5g）を用いて、
実施例３と同様にして、西洋チャボ時計草抽出エキスと
マレイン酸クロルフェニラミンを主薬として含有する錠
剤（3,000錠）を得る。Example 4 Instead of diphenhydramine hydrochloride (25 g) of Example 3, chlorpheniramine maleate (7.5 g) was used.
In the same manner as in Example 3, tablets (3,000 tablets) containing an extract of western chabo (clockwork grass) extract and chlorpheniramine maleate as main ingredients are obtained.
Claims (3)
ン性物質とを有効成分として含有する催眠・鎮静剤。(1) A hypnotic / sedative containing an extract of western chabo watchgrass extract and an antihistamine substance as active ingredients.
ミンである請求項（１）に記載の催眠・鎮静剤。2. The hypnotic / sedative according to claim 1, wherein the antihistamine is diphenhydramine hydrochloride.
ェニラミンである請求項（１）に記載の催眠・鎮静剤。3. The hypnotic / sedative according to claim 1, wherein the antihistamine substance is chlorpheniramine maleate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2143774A JP2943247B2 (en) | 1990-05-31 | 1990-05-31 | Hypnosis / Sedative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2143774A JP2943247B2 (en) | 1990-05-31 | 1990-05-31 | Hypnosis / Sedative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0436243A JPH0436243A (en) | 1992-02-06 |
| JP2943247B2 true JP2943247B2 (en) | 1999-08-30 |
Family
ID=15346708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2143774A Expired - Fee Related JP2943247B2 (en) | 1990-05-31 | 1990-05-31 | Hypnosis / Sedative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2943247B2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004107258A (en) * | 2002-09-18 | 2004-04-08 | Ss Pharmaceut Co Ltd | Hypnotic compression-molded preparation |
| JP4721631B2 (en) * | 2003-09-30 | 2011-07-13 | 小林製薬株式会社 | Hypnotic composition |
| JP4780907B2 (en) * | 2003-09-30 | 2011-09-28 | 小林製薬株式会社 | Hypnotic composition |
| JP4578083B2 (en) * | 2003-09-30 | 2010-11-10 | 小林製薬株式会社 | Hypnotic composition |
| JP4794123B2 (en) * | 2003-09-30 | 2011-10-19 | 小林製薬株式会社 | Hypnotic composition |
| JP2005281268A (en) * | 2004-03-31 | 2005-10-13 | Taiyo Yakuhin Kogyo Kk | Antihistamines solid preparation stable with lapse of time |
| TWI396545B (en) * | 2005-08-15 | 2013-05-21 | Ssp Co Ltd | Pharmaceutical composition for improving sleep |
| AR056076A1 (en) * | 2005-09-20 | 2007-09-19 | Takeda Pharmaceutical | PROFILACTIC OR THERAPEUTIC AGENT FOR SOUND DISORDER |
| JP5380930B2 (en) * | 2007-07-24 | 2014-01-08 | 大正製薬株式会社 | Sleep improver |
| JP5226732B2 (en) * | 2010-05-20 | 2013-07-03 | エスエス製薬株式会社 | Compression molding for hypnosis |
| EA032439B9 (en) | 2013-01-30 | 2019-08-30 | Борис Горинштейн | COMPOSITIONS AND METHODS FOR TREATMENT OF SURFACE RAS |
| GB201302048D0 (en) * | 2013-02-05 | 2013-03-20 | Bennett Christopher F | Forulation with significant sedative properties for possible medical use in anxiety and a hypnotic formulation |
-
1990
- 1990-05-31 JP JP2143774A patent/JP2943247B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0436243A (en) | 1992-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0164435B1 (en) | Pharmaceutical composition for the treatment of obesity | |
| RU2003126257A (en) | A SOLID DOSED MEDICINAL FORM FOR ORAL ADMINISTRATION CONTAINING A COMBINATION OF METFORMINE AND GLYBENCLAMIDE | |
| US4590213A (en) | Anti-anxiety method | |
| US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| JPS6047246B2 (en) | depression medication | |
| EP0629400A1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| JPH0436243A (en) | Hypnotic sedative | |
| US20140275139A1 (en) | Mdr method and products for treating hiv/aids | |
| CN115337348B (en) | Traditional Chinese medicine composition for treating heat-accumulation blood vessels | |
| CN115337347B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| WO1993013787A1 (en) | Immunopotentiating agent | |
| CZ79593A3 (en) | Antitussive preparation | |
| JPH02152926A (en) | Brain edema depressant | |
| JPH04173741A (en) | Agent for preventing and treating hypertension | |
| OLIVER-GONZÁLEZ et al. | TREATMENT OF FILARIASIS BANCROFTI WITH HETRAZAN®: Follow-up Observations Fifteen Months After Treatment | |
| Wiseman et al. | Development of a sustained‐release aspirin tablet | |
| JPS6256435A (en) | Coronary vasodilator | |
| JPS63239229A (en) | Immunoactivating agent | |
| JPH06239763A (en) | Medicine for cold | |
| JPH10306031A (en) | Pharmaceutical preparation of crude drug | |
| JPS5852220A (en) | Lowering agent for uric acid value in blood serum | |
| JPS63190827A (en) | Treating and preventive agent for ulcer and gastritis | |
| JP2000229853A (en) | Menstrual pain improving composition | |
| JPH0967256A (en) | Cold medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080625 Year of fee payment: 9 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080625 Year of fee payment: 9 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |